RxDoctor Payments DataLook up a doctor →

Steven Geller, DO

Pulmonary Disease · Philadelphia, PANPI 1194836387

Payments from drug & device makers

$274,453in general payments, 2019–2025

Across 1,296 payments — averaging $211.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$141K
  • AstraZeneca$99K
  • Regeneron Healthcare Solutions, Inc.$16K
  • Amgen$4K
  • Boehringer Ingelheim$2K
  • United Therapeutics Corporation$1K
  • plus $11K from 42 others

What the payments were for

  • Consulting fees$4,9402%
  • Speaking & faculty fees$233,48485%
  • Travel & lodging$4,8282%
  • Food & beverage$30,42911%
  • Education$7730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$274,453 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$149,936
Medicare patients
583
Services billed
1,623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter750$573,743
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr467$245,655
OfevNintedanib Esylate19$241,023
Breztri AerosphereBudesonide/Glycopyr/Formoterol196$146,530
Breo ElliptaFluticasone/Vilanterol222$98,457
Stiolto RespimatTiotropium Br/Olodaterol Hcl92$45,933
Spiriva RespimatTiotropium Bromide72$43,899
XolairOmalizumab12$32,703
Albuterol Sulfate HfaAlbuterol Sulfate964$29,254
Incruse ElliptaUmeclidinium Bromide75$26,426
Fluticasone-SalmeterolFluticasone Propion/Salmeterol149$23,787
Bevespi AerosphereGlycopyrrolate/Formoterol Fum52$22,249
Spiriva HandihalerTiotropium Bromide35$18,262
SymbicortBudesonide/Formoterol Fumarate67$17,650
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate51$11,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$140,794$949,4551,527 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$1,691$330,855183 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort, Daliresp$99,198$192,196329 claims
MerckDulera$211$4,02112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →